Key points:
- BHVN shares soar 70% on price of $148.50 per share
- A key focus on NURTEC ODT – a dual-acting migraine therapy for adults
- Pfizer is looking to expand its treatment portfolio as the vaccine race fades
Shares of biopharmaceutical company Biohaven Pharmaceutical (NYSE: BHVN) soared 70% after news that it has entered a definitive agreement with Pfizer for the total acquisition of Biohaven for $11.6B in cash. As Pfizer looks to expand its product pipeline after the vaccine sales flurry fades, key therapies like NURTEC ODT – a dual-acting migraine therapy – are catching the eye of industry leaders.
Under the finalized terms of the agreement, Pfizer will pay $148.50 per Biohaven share, and shareholders will also receive half a share of New Biohaven, an entirely new publicly traded entity that will retain Biohaven’s non-calcitonin gene-related principle; development stage pipeline compounds.
Pfizer will make payments by 2023 to settle Biohaven’s third-party debt and redeem preferred stock. The buying price of $148.50 per share amounts to a 33% premium over Biohaven’s volume weighted average selling price of $111.70; spread over the three months prior to the announcement. With a closing price of $83.14 on Monday, price is currently holding a 70% gain at around the price of $141.30.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Nick Lagunowich, Global President of Pfizer Internal Medicine stated:
“Today’s announcement builds on our legacy of delivering breakthroughs for patients living with complex pain disorders and diseases that disproportionately impact women”
We can expect to see a lot more similar buyouts in the coming year. With the pandemic seemingly on its way out, big pharma are no longer occupied with the vaccine race and are looking to build on pre-existing portfolio’s and strong treatment pipelines.
